Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 9 (September)

1. 3D MR spectroscopic imaging in the evaluation of prostate cancer.
   Clin Radiol, 62(10): 921-9. [Abstract] [Full-text]
2. Inherited variation in hormone-regulating genes and prostate cancer survival.
   Clin Cancer Res, 13(17): 5156-61. [Abstract] [Full-text]
3. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
   Clin Cancer Res, 13(17): 5103-8. [Abstract] [Full-text]
4. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility.
   Clin Cancer Res, 13(17): 5056-62. [Abstract] [Full-text]
5. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.
   Clin Cancer Res, 13(17): 5028-33. [Abstract] [Full-text]
6. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
   J Natl Cancer Inst, 99(17): 1296-303. [Abstract] [Full-text]
7. Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.
   J Natl Cancer Inst, 99(17): 1313-27. [Abstract] [Full-text]
8. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines.
   Growth Horm IGF Res, 17(5): 383-91. [Abstract] [Full-text]
9. Clinical safety of a viral vector based prostate cancer vaccine strategy.
   J Urol, 178(4): 1515-20. [Abstract] [Full-text]
10. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
    J Urol, 178(4): 1521-7. [Abstract] [Full-text]
11. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
    J Urol, 178(4): 1528-32. [Abstract] [Full-text]
12. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    J Urol, 178(4): 1423-8. [Abstract] [Full-text]
13. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy.
    J Urol, 178(4): 1306-10. [Abstract] [Full-text]
14. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    J Urol, 178(4): 1290-5. [Abstract] [Full-text]
15. Combined inguinal hernia repair with prosthetic mesh during transperitoneal robot assisted laparoscopic radical prostatectomy: a 4-year experience.
    J Urol, 178(4): 1296-9; discussion 1299-300. [Abstract] [Full-text]
16. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    J Urol, 178(4): 1249-52. [Abstract] [Full-text]
17. Patient identification error among prostate needle core biopsy specimens--are we ready for a DNA time-out?
    J Urol, 178(4): 1245-8. [Abstract] [Full-text]
18. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    J Urol, 178(4): 1277-80; discussion 1280-1. [Abstract] [Full-text]
19. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
    J Urol, 178(4): 1229-36; discussion 1236-7. [Abstract] [Full-text]
20. Advanced but not localized prostate cancer is associated with increased oxidative stress.
    J Urol, 178(4): 1238-43; discussion 1243-4. [Abstract] [Full-text]
21. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    J Urol, 178(4): 1258-63; discussion 1263-4. [Abstract] [Full-text]
22. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome.
    J Urol, 178(4): 1253-7; discussion 1257. [Abstract] [Full-text]
23. Higher frequency of familial clustering of prostate cancer in French-Canadian men.
    J Urol, 178(4): 1265-9; discussion 1270. [Abstract] [Full-text]
24. Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration.
    J Urol, 178(4): 1271-6. [Abstract] [Full-text]
25. Computer modeling technology to assess extracapsular tissue coverage of whole mount sections after retropubic and laparoscopic radical prostatectomy.
    J Urol, 178(4): 1301-5. [Abstract] [Full-text]
26. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    J Urol, 178(4): 1311-5. [Abstract] [Full-text]
27. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    J Urol, 178(4): 1282-8; discussion 1288-9. [Abstract] [Full-text]
28. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.
    Genes Chromosomes Cancer, 46(11): 972-80. [Abstract] [Full-text]
29. Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts.
    Cancer Chemother Pharmacol, 60(6): 821-9. [Abstract] [Full-text]
30. Targeting uPA/uPAR in prostate cancer.
    Cancer Treat Rev, 33(6): 521-7. [Abstract] [Full-text]
31. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.
    Cancer Gene Ther, 14(10): 819-27. [Abstract] [Full-text]
32. Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion.
    Int J Radiat Oncol Biol Phys, 69(2): 614-8. [Abstract] [Full-text]
33. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 69(2): 426-33. [Abstract] [Full-text]
34. Prediction of radial distance of extraprostatic extension from pretherapy factors.
    Int J Radiat Oncol Biol Phys, 69(2): 411-8. [Abstract] [Full-text]
35. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.
    Int J Radiat Oncol Biol Phys, 69(2): 444-53. [Abstract] [Full-text]
36. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers.
    Int J Radiat Oncol Biol Phys, 69(2): 419-25. [Abstract] [Full-text]
37. Acute morbidity of proton therapy for prostate cancer: the Hyogo Ion Beam Medical Center experience.
    Int J Radiat Oncol Biol Phys, 69(2): 434-43. [Abstract] [Full-text]
38. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
    Am J Clin Pathol, 128(4): 657-66. [Abstract] [Full-text]
39. Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia.
    Am J Clin Pathol, 128(4): 648-51. [Abstract] [Full-text]
40. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
    Endocrinology, 148(10): 4716-26. [Abstract] [Full-text]
41. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
    J Natl Cancer Inst, 99(18): 1375-83. [Abstract] [Full-text]
42. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
    J Natl Cancer Inst, 99(18): 1395-400. [Abstract] [Full-text]
43. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    J Natl Cancer Inst, 99(18): 1366-74. [Abstract] [Full-text]
44. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    AJR Am J Roentgenol, 189(4): 849. [Abstract] [Full-text]
45. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer.
    AJR Am J Roentgenol, 189(4): 830-44. [Abstract] [Full-text]
46. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results.
    Radiology, 245(1): 176-85. [Abstract] [Full-text]
47. The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer.
    Onkologie, 30(10): 489-94. [Abstract] [Full-text]
48. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
    Hum Pathol, 38(10): 1547-52. [Abstract] [Full-text]
49. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer.
    Hum Pathol, 38(10): 1501-7. [Abstract] [Full-text]
50. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study.
    Cancer, 110(7): 1485-92. [Abstract] [Full-text]
51. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature.
    Cancer, 110(7): 1417-28. [Abstract] [Full-text]
52. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option.
    Cancer, 110(7): 1405-16. [Abstract] [Full-text]
53. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
    Cancer, 110(7): 1478-84. [Abstract] [Full-text]
54. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Cancer, 110(7): 1493-500. [Abstract] [Full-text]
55. Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer.
    Mol Carcinog, 46(10): 839-46. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.